Status:
UNKNOWN
The Study Design of a Mobile Health (mHealth) Technology Associated Improvement of Drug Adherence in Patients With Acute Myocardial Infarction and Protocol for the Randomized, Controlled Trial（RESCIND-3)
Lead Sponsor:
Guangdong Provincial People's Hospital
Collaborating Sponsors:
Maoming People's Hospital
Dongguan People's Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The RESCIND-3 study is a multicenter, double-blind, randomized controlled trial. It will be conducted in the departments of cardiology in 5 hospitals. Guangdong General Hospital ethics review board ap...
Detailed Description
Background：Antithrombotic drugs, β-blockers, statins and angiotensin converting enzyme inhibitor (ACEI)/angiotensin II receptor blockers (ARB) are recommended for patients with acute myocardial infarc...
Eligibility Criteria
Inclusion
- Aged ≥18 years
- Diagnosed with acute myocardial infarction
- Taking four kinds of cardioprotective medications(antiplatelet, ACEI/ARB, beta-blockers, and statins)
- Wechat and smartphone users
- Provide written informed consent
Exclusion
- Pregnancy
- Malignant tumor or end-stage disease with a life expectancy of \<1 year
- Unable to use mobile phone network applet
- Refuse to sign the informed consent
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04119726
Start Date
January 1 2019
End Date
July 1 2020
Last Update
October 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong General Hospital
Guangzhou, Guangdong, China, 510080